Relay Therapeutics, Inc. (NASDAQ:RLAY – Get Free Report) has received a consensus recommendation of “Buy” from the six brokerages that are presently covering the company, Marketbeat.com reports. Six investment analysts have rated the stock with a buy rating. The average 12 month price target among brokerages that have covered the stock in the last year […]